A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML.

Leuk Res Rep

Department of Internal Medicine, Division of Malignant Hematology, Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, CA, USA.

Published: June 2023

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285270PMC
http://dx.doi.org/10.1016/j.lrr.2023.100374DOI Listing

Publication Analysis

Top Keywords

phase trial
4
trial decitabine
4
decitabine bortezomib
4
bortezomib pegylated
4
pegylated liposomal
4
liposomal doxorubicin
4
doxorubicin treatment
4
treatment relapsed
4
relapsed refractory
4
refractory aml
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!